Reference List - Chapter 8: Autoimmune Polyendocrine Syndromes

(1) Ahonen P, Myllarniemi S, Sipila I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy - candidiasis - ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990; 322 (26):1829-1836.
(2) Schmidt MB. Eine biglandulare Erkrankung (Nebennieren und Schilddruse) bei Morbus Addisonii. Verh Dtsch Ges Pathol 1926; 21:212-221.
(3) Nerup J. Addison's disease - clinical studies: A report of 108 cases. Acta Endocrinol 1974; 76:127-141.
(4) Patel DD. Escape from tolerance in the human X-linked autoimmunity-allergic disregulation syndrome and the Scurfy mouse. J Clin Invest 2001; 107 (2):155-157.
(5) Flier JS, Kahn CR, Roth J, Bar RS. Antibodies that impair insulin receptor binding in an unusual diabetic syndrome with severe insulin resistance. Science 1975; 190:63-65.
(6) Flier JS, Bar RS, Muggeo M, Kahn CR, Roth J, Gorden P. The evolving clinical course of patients with insulin receptor autoantibodies: Spontaneous remission or receptor proliferation with hypoglycemia. J Clin Endocrinol Metab 1978; 47:985-995.
(7) Souadjian JV, Enriquez P, Silverstein MN, Pepin J-M. The spectrum of diseases associated with thymoma. Arch Intern Med 1974; 134:374-379.
(8) Combs RM. Malignant thymoma, hyperthyroidism and immune disorder. South Med J 1968; 61:337-341.
(9) Maggi G, Casadio C, Cavallo A, Cianci R, Molinatti M, Ruffini E. Thymoma: results of 241 operated cases. Ann Thorac Surg 1991; 51:152-156.
(10) Hirata Y, Ishizu H, Ouchi N, Motumura S, Abe M, Hara Y et al. Insulin autoimmunity in a case with spontaneous hypoglycaemia. Japan J Diabetes 1970; 13:312-319.
(11) Uchigata Y, Hirata Y. Insulin Autoimmune Syndrome (IAS, Hirata Disease). In: Eisenbarth G, editor. Molecular Mechanisms of Endocrine and Organ Specific Autoimmunity. Austin, Texas: R.G.Landes, 1999: 133-148.
(12) Imawari M, Akatsuka N, Ishibashi M, Beppu H, Suzuki H, Yoshitoshi Y. Syndrome of plasma cell dyscrasia, polyneuropathy, and endocrine disturbances. Ann Intern Med 1974; 81:490-493.
(13) Miralles GD, O'Fallon JR, Talley NJ. Plasma-cell dyscrasia with polyneuropathy: the spectrum of POEMS syndrome. N Engl J Med 1992; 327 (27):1919-1923.
(14) Eisenbarth GS, Wilson P, Ward F, Lebovitz HE. HLA type and occurrence of disease in familial polyglandular failure. N Engl J Med 1978; 298 (2):92-94.
(15) Perheentupa J. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab 2006; 91 (8):2843-2850.
(16) Betterle C. Parathyroid and autoimmunity. Ann Endocrinol (Paris) 2006; 67 (2):147-154.
(17) Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med 2004; 350 (20):2068-2079.
(18) Mathis D, Benoist C. A decade of AIRE. Nat Rev Immunol 2007; 7 (8):645-650.
(19) Ekwall O, Sjoberg K, Mirakian R, Rorsman F, Kampe O. Tryptophan hydroxylase autoantibodies and intestinal disease in autoimmune polyendocrine syndrome type 1 [letter]. Lancet 1999; 354 (9178):568.
(20) Garty BZ, Kauli R. Alopecia universalis in autoimmune polyglandular syndrome type I. West J Med 1990; 152:76-77.
(21) Ahonen P, Miettinen A, Perheentupa J. Adrenal and steroidal cell antibodies in patients with autoimmune polyglandular disease type I and risk of adrenocortical and ovarian failure. J Clin Endocrinol Metab 1987; 64 (3):494-500.
(22) Mandel M, Etzioni A, Theodor R, Passwell JH. Pure red cell hypoplasia associated with polyglandular autoimmune syndrome type I. Isr J Med Sci 1989; 25:138-141.
(23) Hara T, Mizuno Y, Nagata M, Okabe Y, Taniguchi S, Harada M et al. Human gamma delta T-cell receptor-positive cell-mediated inhibition of erythropoiesis in vitro in a patient with type I autoimmune polyglandular syndrome and pure red blood cell aplasia. Blood 1990; 75:941-950.
(24) Friedman TC, Thomas PM, Fleisher TA, Feuillan P, Parker RI, Cassorla F et al. Frequent occurrence of asplenism and cholelithiasis in patients with autoimmune polyglandular disease type I. Am J Med 1991; 91:625-630.
(25) Hogenauer C, Meyer RL, Netto GJ, Bell D, Little KH, Ferries L et al. Malabsorption due to cholecystokinin deficiency in a patient with autoimmune polyglandular syndrome type I. N Engl J Med 2001; 344 (4):270-274.
(26) Gianani R, Eisenbarth GS. Autoimmunity to gastrointestinal endocrine cells in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 2003; 88 (4):1442-1444.
(27) Skoldberg F, Portela-Gomes GM, Grimelius L, Nilsson G, Perheentupa J, Betterle C et al. Histidine decarboxylase, a pyridoxal phosphate-dependent enzyme, is an autoantigen of gastric enterochromaffin-like cells. J Clin Endocrinol Metab 2003; 88 (4):1445-1452.
(28) De Luca F, Valenzise M, Alaggio R, Arrigo T, Crisafulli G, Salzano G et al. Sicilian family with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) and lethal lung disease in one of the affected brothers. Eur J Pediatr 2008; .
(29) Korniszewski L, Kurzyna M, Stolarski B, Torbicki A, Smerdel A, Ploski R. Fatal primary pulmonary hypertension in a 30-yr-old female with APECED syndrome. Eur Respir J 2003; 22 (4):709-711.
(30) Kumar PG, Laloraya M, She JX. Population genetics and functions of the autoimmune regulator (AIRE). Endocrinol Metab Clin North Am 2002; 31 (2):321-38, vi.
(31) Aaltonen J, Björses P, Sandkuijl L, Perheentupa J, Peltonen L. An autosomal locus causing autoimmune disease: autoimmune polyglandular disease type I assigned to chromosome 21. Nat Genet 1994; 8 (1):83-87.
(32) Aaltonen J, Björses P, Perheentupa J, Horelli-Kuitunen N, Palotie A, Peltonen L et al. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet 1997; 17 (4):399-403.
(33) Myhre AG, Halonen M, Eskelin P, Ekwall O, Hedstrand H, Rorsman F et al. Autoimmune polyendocrine syndrome type 1 (APS I) in Norway. Clin Endocrinol (Oxf) 2001; 54 (2):211-217.
(34) Cavadini P, Vermi W, Facchetti F, Fontana S, Nagafuchi S, Mazzolari E et al. AIRE deficiency in thymus of 2 patients with Omenn syndrome. J Clin Invest 2005; 115 (3):728-732.
(35) Halonen M, Eskelin P, Myhre AG, Perheentupa J, Husebye ES, Kampe O et al. AIRE Mutations and Human Leukocyte Antigen Genotypes as Determinants of the Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy Phenotype. J Clin Endocrinol Metab 2002; 87 (6):2568-2574.
(36) Ramsey C, Winqvist O, Puhakka L, Halonen M, Moro A, Kampe O et al. Aire deficient mice develop multiple features of APECED phenotype and show altered immune response. Hum Mol Genet 2002; 11 (4):397-409.
(37) Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ et al. Projection of an immunological self shadow within the thymus by the aire protein. Science 2002; 298 (5597):1395-1401.
(38) Hanahan D. Peripheral-antigen-expressing cells in thymic medulla: factors in self- tolerance and autoimmunity. Curr Opin Immunol 1998; 10 (6):656-662.
(39) Heath VL, Moore NC, Parnell SM, Mason DW. Intrathymic expression of genes involved in organ specific autoimmune disease. J Autoimmun 1998; 11 (4):309-318.
(40) Vafiadis P, Bennett ST, Todd JA, Nadeau J, Grabs R, Goodyer CG et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet 1997; 15:289-292.
(41) Pugliese A, Zeller M, Fernandez A, Zalcberg LJ, Bartlett RJ, Ricordi C et al. The insulin gene is transcribed in the human thymus and transcription levels correlate with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type I diabetes. Nat Genet 1997; 15 (3):293-297.
(42) Chentoufi AA, Polychronakos C. Insulin expression levels in the thymus modulate insulin-specific autoreactive T-cell tolerance: the mechanism by which the IDDM2 locus may predispose to diabetes. diab 2002; 51 (5):1383-1390.
(43) Pugliese A, Miceli D. The insulin gene in diabetes. Diabetes Metab Res Rev 2002; 18 (1):13-25.
(44) Pugliese A. Peripheral antigen-expressing cells and autoimmunity. Endocrinology and Metabolism Clinics of North America. W.B. Saunders, 2002: 411-30.
(45) Taubert R, Schwendemann J, Kyewski B. Highly variable expression of tissue-restricted self-antigens in human thymus: Implications for self-tolerance and autoimmunity. Eur J Immunol 2007; 37 (3):838-848.
(46) Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, Miao D et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005; 435 (7039):220-223.
(47) Nakayama M, Beilke JN, Jasinski JM, Kobayashi M, Miao D, Li M et al. Priming and effector dependence on insulin B:9-23 peptide in NOD islet autoimmunity. J Clin Invest 2007; 117 (7):1835-1843. Krishnamurthy B, Dudek NL, McKenzie MD, Purcell AW, Brooks AG, Gellert S et al. Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. J Clin Invest 2006; 116 (12):3258-3265.
(49) Krishnamurthy B, Mariana L, Gellert SA, Colman PG, Harrison LC, Lew AM et al. Autoimmunity to Both Proinsulin and IGRP Is Required for Diabetes in Nonobese Diabetic 8.3 TCR Transgenic Mice. J Immunol 2008; 180 (7):4458-4464.
(50) Thebault-Baumont K, Dubois-LaForgue D, Krief P, Briand JP, Halbout P, Vallon-Geoffroy K et al. Acceleration of type 1 diabetes mellitus in proinsulin 2-deficient NOD mice. J Clin Invest 2003; 111 (6):851-857.
(51) Elbein SC, Hoffman MD, Mayorga RA, Barrett KL, Leppert M, Hasstedt S. Do non-insulin dependent diabetes mellitus (NIDDM) and insulin-dependent diabetes mellitus (IDDM) share genetic susceptibility loci? An analysis of putative IDDM susceptibility regions in familial NIDDM. metab 1997; 46 (1):48-52.
(52) Villasenor J, Benoist C, Mathis D. AIRE and APECED: molecular insights into an autoimmune disease. Immunol Rev 2005; 204:156-64.:156-164.
(53) Pugliese A, Brown D, Garza D, Zeller M, Redondo MJ, Eisenbarth GS et al. Self-Antigen Presenting Cells Expressing Islet Cell Molecules in Human Thymus and Peripheral Lymphoid Organs: Phenotypic Characterization and Implications for Immunological Tolerance and Type 1 Diabetes. J Clin Invest 2001; 107 (5):555-564.
(54) Cetani F, Barbesino G, Borsari S, Pardi E, Cianferotti L, Pinchera A et al. A novel mutation of the autoimmune regulator gene in an Italian kindred with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy, acting in a dominant fashion and strongly cosegregating with hypothyroid autoimmune thyroiditis. J Clin Endocrinol Metab 2001; 86 (10):4747-4752.
(55) Su MA, Giang K, Zumer K, Jiang H, Oven I, Rinn JL et al. Mechanisms of an autoimmunity syndrome in mice caused by a dominant mutation in Aire. J Clin Invest 2008; 118 (5):1712-1726.
(56) Perheentupa J, Miettinen A. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. In: Eisenbarth GS, editor. Endocrine and Organ Specific Autoimmunity. Austin: R.G. Landes Company, 1999: 19-40.
(57) De Bellis A, Bizzarro A, Rossi R, Amoresano Paglionico V, Criscuolo T, Lombardi G et al. Remission of subclinical adrenocortical failure in subjects with adrenal autoantibodies. J Clin Endocrinol Metab 1993; 76:1002-1007.
(58) Clemente MG, Obermayer-Straub P, Meloni A, Strassburg CP, Arangino V, Tukey RH et al. Cytochrome P450 1A2 is a hepatic autoantigen in autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab 1997; 82 (5):1353-1361.
(59) Radetti G, Paganini C, Gentili L, Bernasconi S, Beterle C, Borkenstein M et al. Frequency of Hashimoto's thyroiditis in children with type 1 diabetes mellitus. Acta Diabetol 1995; 32:121-124.
(60) Landin-Olsson M, Karlsson FA, Lernmark Å, Sundkvist G, and the Diabetes Incidence Study in Sweden Group. Islet cell and thyrogastric antibodies in 633 consecutive 15- to 34-yr-old patients in the diabetes incidence study in Sweden. diab 1992; 41:1022-1027.
(61) Fairfax AJ, Leatham A. Idiopathic heart block: association with vitiligo, thyroid disease, pernicious anemia, and diabetes mellitus. BMJ 1975; 4 (5992):322-324.
(62) Davis RE, VcCann VJ, Stanton KG. Type 1 diabetes and latent pernicious anaemia. Med J Aust 1992; 156 (3):160-162.
(63) Peserico A, Rigon F, Semsenzato G, Caretto A, Pasini CV, Betterle C. Vitiligo and polyglandular autoimmune disease with autoantibodies to melanin-producing cells. A new syndrome? Arch Dermatol 1981; 117 (11):751-752.
(64) Betterle C, Caretto A, Pedini B, Rigon F, Bertoli P, Peserico A. Complement-fixing activity to melanin-producing cells preceding the onset of vitiligo in a patient with type I polyglandular failure. Arch Dermatol 1995; 128:123-124.
(65) Torrelo A, España A, Balsa J, Ledo A. Vitiligo and polyglandular autoimmune syndrome with selective IgA deficiency. Int J Dermatol 1992; 31 (5):343-344.
(66) Stankler L, Bewsher PD. Chronic mucocutaneous candidiasis endocrine deficiency and alopecia areata. Br J Dermatol 1972; 86 (3):238-245.
(67) Hedstrand H, Perheentupa J, Ekwall O, Gustafsson J, Michaelsson G, Husebye E et al. Antibodies against hair follicles are associated with alopecia totalis in autoimmune polyendocrine syndrome type I. J Invest Dermatol 1999; 113 (6):1054-1058.
(68) Bosch EP, Reith PE, Granner DK. Myasthenia gravis and Schmidt syndrome. Semin Neurol 1994; 27:1179-1180.
(69) Marino M, Ricciardi R, Pinchera A, Barbesino G, Manetti L, Chiovato L et al. Mild clinical expression of myasthenia gravis associated with autoimmune thyroid diseases. J Clin Endocrinol Metab 1997; 82 (2):438-443.
(70) Collin P, Salmi J, Hällström O, Reunala T, Pasternack A. Autoimmune thyroid disorders and coeliac disease. Eur J Endocrinol 1994; 130:137-140.
(71) Reijonen H, Ilonen J, Knip M, Reunala T. Insulin-dependent diabetes mellitus associated with dermatitis herpetiformis: evidence for heterogeneity of HLA-associated genes. Tissue Antigens 1991; 37:94-96.
(72) Reunala T, Salmi J, Karvonen J. Dermatitis herpetiformis and celiac disease associated with Addison's disease. Arch Dermatol 1987; 123:930-932.
(73) Tucker WSJr, Niblack GD, McLean RH, Alspaugh MA, Wyatt RJ, Jordan SC et al. Serositis with autoimmune endocrinopathy: clinical and immunogenetic features. Medicine 1987; 66 (2):138-147.
(74) Merenmies L, Tarkkanen A. Chronic bilateral keratitis in autoimmune polyendocrinopathy-candidiadis-ectodermal dystrophy (APECED). A long-term follow-up and visual prognosis [In Process Citation]. Acta Ophthalmol Scand 2000; 78 (5):532-535.
(75) Turkington RW, Lebovitz HE. Extra-adrenal endocrine deficiencies in Addison's disease. Am J Med 1967; 43:499-507.
(76) Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 1990; 322 (22):1555-1560.
(77) Selinger S, Tsai J, Pulini M, Saperstein A, Taylor S. Autoimmune thrombocytopenia and primary billary cirrhosis with hypoglycemia and insulin receptor autoantibodies. Ann Intern Med 1987; 107:686-688.
(78) Rhim SH, Millar SE, Robey F, Luo AM, Lou YH, Yule T et al. Autoimmune disease of the ovary induced by a ZP3 peptide from the mouse zona pellucida. J Clin Invest 1992; 89:28-35.
(79) Muir A, Maclaren NK. Autoimmune diseases of the adrenal glands, parathyroid glands, gonads, and hypothalamic-pituitary axis. Endocrinol Metab Clin North Am 1991; 20:619-644.
(80) Barkan AL, Kelch RP, Marshall JC. Isolated gonadotrope failure in the polyglandular autoimmune syndrome. N Engl J Med 1985; 312:1535-1540.
(81) Petersen JS, Dyrberg T, Karlsen AE, Molvig J, Michelsen B, Nerup J et al. Glutamic acid decarboxylase (GAD65) autoantibodies in prediction of B-cell function and remission in recent-onset IDDM after cyclosporin treatment. diab 1994; 43 (11):1291-1296.
(82) Alimohammadi M, Bjorklund P, Hallgren A, Pontynen N, Szinnai G, Shikama N et al. Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen. N Engl J Med 2008; 358 (10):1018-1028.
(83) Efthimiou P, Flavell RA, Furlan A, Gasbarrini G, Gava A, Kone-Paut I et al. Autoinflammatory syndromes and infections: pathogenetic and clinical implications. Clin Exp Rheumatol 2008; 26 (1 Suppl 48):S53-S61.
(84) Martinon F. Detection of immune danger signals by NALP3. J Leukoc Biol 2008; 83 (3):507-511.
(85) Petrilli V, Dostert C, Muruve DA, Tschopp J. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol 2007; 19 (6):615-622.
(86) Pope RM, Tschopp J. The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis Rheum 2007; 56 (10):3183-3188.
(87) Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008; 453 (7198):1122-1126.
(88) Spritz RA. The genetics of generalized vitiligo and associated autoimmune diseases. J Dermatol Sci 2006; 41 (1):3-10.
(89) Soderbergh A, Rorsman F, Halonen M, Ekwall O, Bjorses P, Kampe O et al. Autoantibodies against aromatic L-amino acid decarboxylase identifies a subgroup of patients with Addison's disease. J Clin Endocrinol Metab 2000; 85 (1):460-463.
(90) Gylling M, Tuomi T, Bjorses P, Kontiainen S, Partanen J, Christie MR et al. ss-Cell Autoantibodies, Human Leukocyte Antigen II Alleles, and Type 1 Diabetes in Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy. J Clin Endocrinol Metab 2000; 85 (12):4434-4440.
(91) Ekwall O, Hedstrand H, Haavik J, Perheentupa J, Betterle C, Gustafsson J et al. Pteridin-dependent hydroxylases as autoantigens in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 2000; 85 (8):2944-2950.
(92) Perniola R, Falorni A, Clemente MG, Forini F, Accogli E, Lobreglio G. Organ-specific and non-organ-specific autoantibodies in children and young adults with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) [In Process Citation]. Eur J Endocrinol 2000; 143 (4):497-503.
(93) Soderbergh A, Myhre AG, Ekwall O, Gebre-Medhin G, Hedstrand H, Landgren E et al. Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 2004; 89 (2):557-562.
(94) Meager A, Visvalingam K, Peterson P, Moll K, Murumagi A, Krohn K et al. Anti-Interferon Autoantibodies in Autoimmune Polyendocrinopathy Syndrome Type 1. PLoS Med 2006; 3 (7):e289.
(95) Zhang L, Nakayama M, Eisenbarth GS. Insulin as an autoantigen in NOD/human diabetes. Curr Opin Immunol 2008; .
(96) Perheentupa J. APS-I/APECED: The clinical disease and therapy. In: Eisenbarth GS, editor. Autoimmune Polyendocrine Syndromes. Philadelphia: W.B. Saunders Company, 2002: 295-320.
(97) Walker DA, Davies M. Addison's disease presenting as a hypercalcemic crisis in a patient with idiopathic hypoparathyroidism. Clin Endocrinol (Oxf) 1981; 14 (4):419-423.
(98) Pollak U, Bar-Sever Z, Hoffer V, Marcus N, Scheuerman O, Garty BZ. Asplenia and functional hyposplenism in autoimmune polyglandular syndrome type 1. Eur J Pediatr 2008; .
(99) Ahonen P, Myllarniemi S, Kahanpaa A, Perheentupa J. Ketoconazole is effective against the chronic mucocutaneous candidosis of autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy (APECED). Acta Med Scand 1986; 220 (4):333-339.
(100) Starzyk J, Kumorowicz-Kopiec M, Kowalczyk M, Starzyk B, Rybakowa M, Dziatkowiak H. Natural history of asplenism in APECED--patient report. J Pediatr Endocrinol Metab 2001; 14 (4):443-449.
(101) Betterle C, Volpato M, Greggio AN, Presotto F. Type 2 polyglandular autoimmune disease ISchmitd's syndrome). J Pediatr Endocrinol Metab 1996; 9:113-123.
(102) Savilahti E, Simell O, Koskimies S, Rilva A, Åkerblom HK. Celiac disease in insulin-dependent diabetes mellitus. J Pediatr 1986; 108 (5 Pt 1):690-693.
(103) Bao F, Yu L, Babu S, Wang T, Hoffenberg EJ, Rewers M et al. One third of HLA DQ2 homozygous patients with type 1 diabetes express celiac disease associated transglutaminase autoantibodies. J Autoimmunity 1999; 13:143-148.
(104) Papadopoulos KI, Hornblad Y, Hallengren B. The occurrence of polyglandular autoimmune syndrome type III associated with coeliac disease in patients with sarcoidosis. J Intern Med 1994; 236:661-663.
(105) Furmaniak J, Sanders J, Rees Smith B. Autoantigens in the autoimmune endocrinopathies. In: Volpe R, editor. Contemporary Endocrinology: Autoimmune Endocrinopathies. Totowa: Humana Press Inc., 1999: 183-216.
(106) Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007; 39 (7):857-864. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004; 36 (4):337-338.
(108) Skinningsrud B, Husebye ES, Gervin K, Lovas K, Blomhoff A, Wolff AB et al. Mutation screening of PTPN22: association of the 1858T-allele with Addison's disease. Eur J Hum Genet 2008; .
(109) Lee YH, Rho YH, Choi SJ, Ji JD, Song GG, Nath SK et al. The PTPN22 C1858T functional polymorphism and autoimmune diseases--a meta-analysis. Rheumatology (Oxford) 2007; 46 (1):49-56.
(110) Barker JM. Clinical review: Type 1 diabetes-associated autoimmunity: natural history, genetic associations, and screening. J Clin Endocrinol Metab 2006; 91 (4):1210-1217.
(111) Kahles H, Ramos-Lopez E, Lange B, Zwermann O, Reincke M, Badenhoop K. Sex-specific association of PTPN22 1858T with type 1 diabetes but not with Hashimoto's thyroiditis or Addison's disease in the German population. Eur J Endocrinol 2005; 153 (6):895-899.
(112) Perez dN, Martin-Pagola A, Ramon BJ, Vazquez F, Castano L. No evidence of association of CTLA4 polymorphisms with Addison's disease. Autoimmunity 2004; 37 (6-7):453-456.
(113) Blomhoff A, Lie BA, Myhre AG, Kemp EH, Weetman AP, Akselsen HE et al. Polymorphisms in the cytotoxic T lymphocyte antigen-4 gene region confer susceptibility to Addison's disease. J Clin Endocrinol Metab 2004; 89 (7):3474-3476.
(114) Donner H, Braun J, Seidl C, Rau H, Finke R, Ventz M et al. Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in Hashimoto's thyroiditis and Addison's disease. J Clin Endocrinol Metab 1997; 82 (12):4130-4132.
(115) Zeitlin AA, Heward JM, Newby PR, Carr-Smith JD, Franklyn JA, Gough SC et al. Analysis of HLA class II genes in Hashimoto's thyroiditis reveals differences compared to Graves' disease. Genes Immun 2008; 9 (4):358-363.
(116) Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, Duncanson A et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007; 39 (11):1329-1337.
(117) Jacobson EM, Tomer Y. The genetic basis of thyroid autoimmunity. Thyroid 2007; 17 (10):949-961.
(118) Yu L, Brewer KW, Gates S, Wu A, Wang T, Babu S et al. DRB1*04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison's disease. J Clin Endocrinol Metab 1999; 84 (1):328-335.
(119) Myhre AG, Undlien DE, Lovas K, Uhlving S, Nedrebo BG, Kristian JF et al. Autoimmune adrenocortical failure in Norway: Autoantibodies and HLA class II associations related to clinical features. J Clin Endocrinol Metab 2002; 87 (2):618-623.
(120) Gombos Z, Hermann R, Kiviniemi M, Nejentsev S, Reimand K, Fadeyev V et al. Analysis of extended human leukocyte antigen haplotype association with Addison's disease in three populations. Eur J Endocrinol 2007; 157 (6):757-761.
(121) Eisenbarth GS, Wilson PW, Ward F, Buckley C, Lebovitz HE. The polyglandular failure syndrome: disease inheritance, HLA- type and immune function. Ann Intern Med 1979; 91 (4):528-533.
(122) Maclaren NK, Riley WJ. Inherited susceptibility to autoimmune Addison's disease is linked to human leukocyte antigens-DR3 and/or DR4, except when associated with type 1 autoimmune polyglandular syndrome. J Clin Endocrinol Metab 1986; 62 (3):455-459.
(123) Butler MG, Hodes ME, Conneally PM, Biegel AA, Wright JC. Linkage analysis in a large kindred with autosomal dominant transmission of polyglandular autoimmune disease type II (Schmidt syndrome). Am J Med Genet 1984; 18:61-65.
(124) Farid NR, Larsen B, Payne R, Noel EP, Sampson L. Polyglandular autoimmune disease and HLA. Tissue Antigens 1980; 16:23-29.
(125) Valenta LJ, Bull RW, Hackel E, Bottazzo GF. Correlation of the HLA-A1, B8 haplotypes with circulating autoantibodies in a family with increased incidence of autoimmune disease. Acta Endocrinol 1982; 100 (1):143-149.
(126) Liblau RS, Caillat-Zucman S, Fischer AM, Bach JF, Boitard C. The prevalence of selective IgA deficiency in type 1 diabetes mellitus. Acta Pathol Microbiol Immunol Scand 1992; 100:709-712.
(127) French MAH, Dawkins RL. Central MHC genes, IgA deficiency and autoimmune disease. Immunol Today 1990; 11 (8):271-274.
(128) Alper CA, Marcus-Bagley D, Awdeh Z, Kruskall MS, Eisenbarth GS, Brink SJ et al. Prospective analysis suggests susceptibility genes for deficiencies of IgA and several other immunoglobulins on the [HLA-B8, SC01, DR3] conserved extended haplotype. Tissue Antigens 2000; 56 (3):207-216.
(129) Valenta LJ, Elias AN. Familial scleroderma in a kindred with high incidence of autoimmune disease: correlation with HLA-A1/B8 haplotype. Arch Dermatol 1987; 123:1438-1440.
(130) Candrina R, Giustina A. Development of type II autoimmune polyglandular syndrome in a patient with idiopathic thrombocytopenic purpura. Isr J Med Sci 1988; 24:57-58.
(131) Vela BS, Dorin RI, Hartshorne MF. Case report 631: Neo-osseous porosis (metaphyseal osteopenia) in polyglandular autoimmune (Schmidt) syndrome. Skeletal Radiol 1990; 19:468-471.
(132) Simmonds MJ, Howson JM, Heward JM, Carr-Smith J, Franklyn JA, Todd JA et al. A novel and major association of HLA-C in Graves' disease that eclipses the classical HLA-DRB1 effect. Hum Mol Genet 2007; 16 (18):2149-2153.
(133) Bloch MH, Sowers JR. Vitiligo and polyglandular autoimmune endocrinopathy. Cutis 1985; 36:417-419.
(134) Petite J, Rosset N, Chapuis B, Jeannet M. Genetic factors predisposing to autoimmune diseases. Study of HLA antigens in a family with pernicious anemia and thyroid diseases. Schweiz Med Wochenschr 1987; 117 (50):2032-2037.
(135) Inoue D, Sato K, Sugawa H, Akamizu T, Maeda M, Inoko H et al. Apparent genetic difference between hypothyroid patients with blocking-type thyrotropin receptor antibody and those without, as shown by restriction fragment length polymorphism analyses of HLA-DP loci. J Clin Endocrinol Metab 1993; 77 (3):606-610.
(136) Cho BY, Chung JH, Shong YK, Chang YB, Han H, Lee J-B et al. A strong association between thyrotropin receptor-blocking antibody-positive atrophic autoimmune thyroiditis and HLAL-DR8 and HLA-DQB1*0302 in Koreans. J Clin Endocrinol Metab 1993; 77 (3):611-615.
(137) Santamaria P, Barbosa JJ, Lindstrom AL, Lemke TA, Goetz FC, Rich SS. HLA-DQB1-associated susceptibility that distinguishes Hashimoto's thyroiditis from Graves' disease in type I diabetic patients. J Clin Endocrinol Metab 1994; 78 (4):878-883.
(138) Gambelunghe G, Falorni A, Ghaderi M, Laureti S, Tortoioli C, Santeusanio F et al. Microsatellite Polymorphism of the MHC Class I Chain-related (MIC-A and MIC-B) Genes Marks the Risk for Autoimmune Addison's Disease. J Clin Endocrinol Metab 1999; 84:3701-3707.
(139) Kristiansen OP, Larsen ZM, Pociot F. CTLA-4 in autoimmune diseases--a general susceptibility gene to autoimmunity? Genes Immun 2000; 1 (3):170-184.
(140) Park YS, Sanjeevi CB, Robles D, Yu L, Rewers M, Gottlieb PA et al. Additional association of intra-MHC genes, MICA and D6S273, with Addison's disease. Tissue Antigens 2002; 60 (2):155-163.
(141) Norris JM, Barriga K, Hoffenberg EJ, Taki I, Miao D, Haas JE et al. Risk of celiac disease autoimmunity and timing of gluten introduction in the diet of infants at increased risk of disease. JAMA 2005; 293 (19):2343-2351.
(142) Drosos AA, Christou L, Galanopoulou V, Tzioufas AG, Tsiakou EK. D-penicillamine induced myasthenia gravis: clinical, serological and genetic findings. Clin Exp Rheumatol 1993; 11:387-391.
(143) Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999; 354 (9191):1691-1695.
(144) Schreuder TC, Gelderblom HC, Weegink CJ, Hamann D, Reesink HW, Devries JH et al. High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection. Liver Int 2008; 28 (1):39-46.
(145) Schreuder TC, Gelderblom HC, Weegink CJ, Hamann D, Reesink HW, Devries JH et al. High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection. Liver Int 2007; .
(146) Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Archimandritis AJ. Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol 2007; 13 (8):1292-1294.
(147) Tomer Y, Blackard JT, Akeno N. Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am 2007; 36 (4):1051-1066.
(148) Badra G, Waked I, Selmi C, Saleh SM, El Shaarawy A, Lotfy M. Serum islet cell autoantibodies during interferon alpha treatment in patients with HCV-genotype 4 chronic hepatitis. Clin Dev Immunol 2006; 13 (1):11-15.
(149) Liu E, Li M, Emery L, Taki I, Barriga K, Tiberti C et al. Natural history of antibodies to deamidated gliadin peptides and transglutaminase in early childhood celiac disease. J Pediatr Gastroenterol Nutr 2007; 45 (3):293-300. Hoffenberg EJ, Haas J, Drescher A, Barnhurst R, Osberg I, Bao F et al. A trial of oats in newly diagnosed celiac disease. J Pediatr 2000; 137 (3):361-366.
(151) Green PH, Cellier C. Celiac disease. N Engl J Med 2007; 357 (17):1731-1743.
(152) Atkinson MA, Bowman MA, Kao K, Campbell L, Dush PJ, Shah SC et al. Lack of immune responsiveness to bovine serum albumin in insulin- dependent diabetes. N Engl J Med 1993; 329:1853-1858.
(153) Norris JM, Yin X, Lamb MM, Barriga K, Seifert J, Hoffman M et al. Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes. JAMA 2007; 298 (12):1420-1428. Burman P, Totterman TH, Oberg K, Karlsson FA. Thyroid autoimmunity in patients on long term therapy with leukocyte- derived interferon. J Clin Endocrinol Metab 1986; 63:1086-1090.
(155) Papo T, Oksenhendler E, Izembart M, Leger A, Clauvel J-P. Antithyroid hormone antibodies induced by interferon-a. J Clin Endocrinol Metab 1992; 75:1484-1486.
(156) Gisslinger H, Gilly B, Woloszczuk W, Mayr WR, Havelec L, Linkesch W et al. Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha. Clin Exp Immunol 1992; 90:363-367.
(157) Schilling RF. Who has vitamin B12 deficiency? Proc Assoc Am Physicians 1996; 108 (1):68-70.
(158) de Carmo S, Kater CE, Dib SA, Laureti S, Forini F, Cosentino A et al. Autoantibodies against recombinant human steroidogenic enzymes 21-hydroxylase, side-chain cleavage and 17alpha-hydroxylase in Addison's disease and autoimmune polyendocrine syndrome type III. Eur J Endocrinol 2000; 142 (2):187-194.
(159) Bosi E, Becker F, Bonifacio E, Wagner R, Collins P, Gale EA et al. Progression to type I diabetes in autoimmune endocrine patients with islet cell antibodies. diab 1991; 40 (8):977-984.
(160) Wagner R, Genovese S, Bosi E, Becker F, Bingley PJ, Bonifacio E et al. Slow metabolic deterioration towards diabetes in islet cell antibody positive patients with autoimmune polyendocrine disease. diabetol 1994; 37:365-371.
(161) Blizzard RM, Kyle M. Studies of the adrenal antigens and antibodies in Addison's disease. J Clin Invest 1963; 42:1653-1660.
(162) Soderbergh A, Winqvist O, Norheim I, Rorsman F, Husebye ES, Dolva O et al. Adrenal autoantibodies and organ-specific autoimmunity in patients with Addison's disease. Clin Endocrinol (Oxf) 1996; 45:453-460.
(163) Julien JF, Samama P, Mallet J. Rat brain glutamic acid deciarboxylase sequence deduced from a cloned cDNA. J Neurochem 1990; 54 (2):703-705.
(164) Betterle C, Volpato M, Rees Smith B, Furmaniak J, Chen S, Zanchetta R et al. II. Adrenal cortex and steroid 21-hydroxylase autoantibodies in children with organ-specific autoimmune diseases: markers of high progression to clinical Addison's disease. J Clin Endocrinol Metab 1997; 82 (3):939-942.
(165) Tung KSK, Taguchi O, Teuscher C. Testicular and ovarian autoimmune diseases. 1993.
(166) Coco G, Dal Pra C, Presotto F, Albergoni MP, Canova C, Pedini B et al. Estimated risk for developing autoimmune Addison's disease in patients with adrenal cortex autoantibodies. J Clin Endocrinol Metab 2006; 91 (5):1637-1645.
(167) Posillico JT, Wortsman J, Srikanta S, Eisenbarth GS, Malette LE, Brown EM. Parathyroid cell surface autoantibodies that inhibit parathyroid hormone secretion from dispersed human parathyroid cells. Bone Miner Res 1986; 1 (5):475-483.
(168) Posillico JT, Srikanta S, Eisenbarth G, Quaranta V, Kajiji S, Brown EM. Binding of monoclonal antibody (4F2) to its cell surface antigen on dispersed adenomatous parathyroid cells raises cytosolic calcium and inhibits parathyroid secretion. J Clin Endocrinol Metab 1987; 64 (1):43-50.
(169) Bach J-F, Yamamoto AM, Djabiri F, Garchon H-J. Etiopathogenesis of myasthenia gravis (MG). In: Eisenbarth GS, editor. Molecular mechanisms of endocrine and organ specific autoimmunity. Georgetown: Landes Bioscience, 1997.
(170) Sanders J, Oda Y, Roberts S, Kiddie A, Richards T, Bolton J et al. The interaction of TSH receptor autoantibodies with 125I-labelled TSH receptor. J Clin Endocrinol Metab 1999; 84 (10):3797-3802.
(171) Karlsson FA, Burman P, Loof L, Mardh S. Major parietal cell antigen in autoimmune gastritis and pernicious anemia is the acid producing HK-ATPase of the stomach. J Clin Invest 1988; 81:475-479.
(172) De Block CE, De L, I, Van Gaal LF. High prevalence of manifestations of gastric autoimmunity in parietal cell antibody-positive type 1 (insulin-dependent) diabetic patients. The Belgian Diabetes Registry. J Clin Endocrinol Metab 1999; 84 (11):4062-4067.
(173) Bjork E, Velloso LA, Kampe O, Karlsson FA. GAD autoantibodies in IDDM, stiff-man syndrome, and autoimmune polyendocrine syndrome type I recognize different epitopes. Diabetes 1994; 43 (1):161-165.
(174) Liu E, Eisenbarth GS. Accepting clocks that tell time poorly: fluid-phase versus standard ELISA autoantibody assays. Clin Immunol 2007; 125 (2):120-126.
(175) Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007; 104 (43):17040-17045.
(176) Takasu N, Yamada T, Takasu M, Komiya I, Nagasawa Y, Asawa T et al. Disappearance of thyrotropin-blocking antibodies and spontaneous recovery from hypothyroidism in autoimmune thyroiditis. N Engl J Med 1992; 326 (8):513-518.
(177) Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA et al. Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. J Autoimmun 1996; 9 (3):379-383.
(178) Kita M, Ahmad L, Marians RC, Vlase H, Unger P, Graves PN et al. Regulation and transfer of a murine model of thyrotropin receptor antibody mediated Graves' disease. Endocrinology 1999; 140 (3):1392-1398.
(179) Hirata Y, Ishizu H. Elevated insulin-binding capacity of serum proteins in a case of spontaneous hypoglycemia and mild diabetes not treated with insulin. Tohoku J Exp Med 1972; 107:277-286.
(180) Abiru N, Maniatis AK, Yu L, Miao D, Moriyama H, Wegmann D et al. Peptide and MHC specific breaking of humoral tolerance to native insulin with the B:9-23 peptide in diabetes prone and normal mice. diab 2001; 50:1274-1281.
(181) Cohen IR, Young DB. Autoimmunity, microbial immunity and the immunological homunculus. Immunol Today 1991; 105:105-110.
(182) Wucherpfennig KW. Mechanisms for the induction of autoimmunity by infectious agents. Journal of Clinical Investigation 2001; 108 (8):1097-1104.
(183) Zhang Z-G, Wall JR, Bernard NF. Tissue distribution and quantitation of a gene expressing a 64-kDa antigen associated with thyroid-associated ophthalmopathy. Clin Immunol Immunopathol 1996; 80:236-244.
(184) Stumbles PA, Penhale WJ. IDDM in rats induced by thymectomy and irradiation. diab 1993; 42:571-578.
(185) Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299 (5609):1057-1061.
(186) Sakaguchi S. Policing the regulators. Nat Immunol 2001; 2 (4):283-284.
(187) Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155 (3):1151-1164.
(188) Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T. Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J Exp Med 1985; 161 (1):72-87.
(189) Ramanathan S, Bihoreau MT, Paterson AD, Marandi L, Gauguier D, Poussier P. Thymectomy and radiation-induced type 1 diabetes in nonlymphopenic BB rats. diab 2002; 51 (10):2975-2981.
(190) Stephens LA, Mason D. CD25 is a marker for CD4+ thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25+ and. J Immunol 2000; 165 (6):3105-3110.
(191) Matsuki K, Juji T, Tokunaga K, Takamizawa M, Maeda H, Soda M et al. HLA antigens in japanese patients with myasthenia gravis. J Clin Invest 1990; 392:399.
(192) Garlepp MI, Dawkins RL, Christiansen FT. HLA antigens and acetylcholine receptor antibodies in penicillamine induced myasthenia gravis. BMJ 1983; 286 (6375):1442-1443.
(193) Nagvekar N, Moody AM, Moss P, Roxanis I, Curnow J, Beeson D et al. A pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4- producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes. J Clin Invest 1998; 101 (10):2268-2277.
(194) Taylor SI, Grunberger G, Marcus-Samuels B, Underhill LH, Dons RF, Ryan J et al. Hypoglycemia associated with antibodies to the insulin receptor. N Engl J Med 1982; 307:1422-1426.
(195) Dons RF, Havlik R, Taylor SI, Baird KL, Chernick SS, Gorden P. Clinical disorders associated with autoantibodies to the insulin receptor. J Clin Invest 1992.
(196) Uchigata Y, Kuwata S, Tsushima T, Tokunaga K, Miyamoto M, Tsuchikawa K et al. Patients with Graves' disease who developed insulin autoimmune syndrome (Hirata disease) possess HLA-Bw62/Cw4/DR4 carrying DRB1*0406. J Clin Endocrinol Metab 1993; 77:249-254.
(197) Mcevoy RC, Fedun B, Cooper LZ, Thomas NM, Rodriguez de Cordoba S, Rubinstein P et al. Children at high risk of diabetes mellitus: New York studies of families with diabetes and of children with congenital rubella syndrome. Adv Exp Med Biol 1988; 246:221-227.
(198) Rabinowe SL, Larsen PR, Antman EM, George KL, Friedman PL, Jackson RA et al. Amiodarone therapy and autoimmune thyroid disease. Increase in a new monoclonal antibody-defined T cell subset. Am J Med 1986; 81 (1):53-57.
(199) Shi Y, Zou M, Robb D, Farid NR. Typing for major histocompatibility complex class II antigens in thyroid tissue blocks: association of Hashimoto's thyroiditis with HLA-DQA0301 and DQB0201 alleles. J Clin Endocrinol Metab 1992; 75:943-946.
(200) Tomer Y, Barbesino G, Greenberg DA, Concepcion E, Davies TF. Mapping the major susceptibility loci for familial Graves' and Hashimoto's diseases: evidence for genetic heterogeneity and gene interactions. J Clin Endocrinol Metab 1999; 84 (12):4656-4664.
(201) Badenhoop K, Walfish PG, Rau H, Fischer S, Nicolay A, Bogner U et al. Susceptibility and resistance alleles of human leukocyte antigen (HLA) DQA1 and HLA DQB1 are shared in endocrine autoimmune disease. J Clin Endocrinol Metab 1995; 80 (7):2112-2117.
(202) De Block CE. [Diabetes mellitus type 1 and associated organ-specific autoimmunity]. Verh K Acad Geneeskd Belg 2000; 62 (4):285-328.
(203) Naughton GK, Eisenger M, Bystryn J-C. Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. J Invest Dermatol 1983; 81 (6):540-542.
(204) Xie Z, Chen D, Jiao D, Bystryn JC. Vitiligo antibodies are not directed to tyrosinase. Arch Dermatol 1999; 135 (4):417-422.
(205) Nicholson LB, Wong FS, Ewins DL, Butler J, Holland A, Denaine AG et al. Susceptibility to autoimmune thyroiditis in Down's syndrome is associated with the major histocompatibility complex class II DQA*0301 allele. Clin Endocrinol 1994; 41:381-383.
(206) Larizza D, Bianchi MM, Lorini R, Maghnie M, Dugoujon JM, Belvedere CM et al. Autoimmunity, HLA, Gm and Km polymorphism in Turner's syndrome. Autoimmunity 1989; 4:69-78.
(207) Failla P, Ruberto C, Pagano MC, Lombardo M, Bottaro G, Perichon B et al. Celiac disease in Down's syndrome with HLA serological and molecular studies. J Pediatr Gastroenterol Nutr 1996; 23:303-306.
(208) Fleming S, Cowell C, Bailey J, Burrow GN. Hashimoto's disease in Turner's syndrome. Clin Invest Med 1988; 11 (4):243-246.
(209) Kriegel MA, Lohmann T, Gabler C, Blank N, Kalden JR, Lorenz HM. Defective Suppressor Function of Human CD4+ CD25+ Regulatory T Cells in Autoimmune Polyglandular Syndrome Type II. J Exp Med 2004; 199 (9):1285-1291.
(210) Martin AM, Maxson MN, Leif J, Mordes JP, Greiner DL, Blankenhorn EP. Diabetes-prone and diabetes-resistant BB rats share a common major diabetes susceptibility locus, iddm4: additional evidence for a "universal autoimmunity locus" on rat chromosome 4. diab 1999; 48 (11):2138-2144.
(211) Schranz DB, Lernmark A. Immunology in diabetes: an update. Diabetes Metab Rev 1998; 14 (1):3-29.
(212) Petterson A, Jacob H, Lernmark Å. Lessons from the animal models: the BB rat. In: Palmer JP, editor. Prediction, prevention, and genetic counseling in IDDM. Chichester, England: Wiley, 1996: 181-201.
(213) Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2001; 2 (9):816-822.
(214) Olsen NJ, Brooks RH, Cush JJ, Lipsky PE, St Clair EW, Matteson EL et al. A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group. Arthritis Rheum 1996; 39 (7):1102-1108.
(215) Wildin RS, Freitas A. IPEX and FOXP3: Clinical and research perspectives. J Autoimmun 2005; 25 Suppl:56-62.
(216) Jackson RA, Haynes BF, Burch WM, Shimizu K, Bowring MA, Eisenbarth GS. Ia+ T cells in new onset Graves' disease. J Clin Endocrinol Metab 1984; 59 (2):187-190.
(217) Kaye WA, Adri MN, Soeldner JS, Kaldany A, Rabinowe SL, Kahn CR et al. Acquired defect in interleukin-2 production in patients with type I diabetes mellitus. N Engl J Med 1986; 315 (15):920-924.
(218) Wilson SB, Kent SC, Patton KT, Orban T, Jackson RA, Exley M et al. Extreme Th1 bias of invariant Va24JaQ T cells in type 1 diabetes. Nature 1998; 391:177-181.
(219) Lee PT, Putnam A, Benlagha K, Teyton L, Gottlieb PA, Bendelac A. Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 2002; 110 (6):793-800.
(220) Dittmar M, Kahaly GJ. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J Clin Endocrinol Metab 2003; 88 (7):2983-2992.
(221) Tursi A, Brandimarte G, Giorgetti GM. TI - Prevalence of antitissue transglutaminase antibodies in different degrees of intestinal damage in celiac disease.
(222) Freemark M, Levitsky LL. Screening for Celiac Disease in Children With Type 1 Diabetes: Two views of the controversy. Diab care 2003; 26 (6):1932-1939.
(223) Cronin CC, Feighery A, Ferriss JB, Liddy C, Shanahan F, Feighery C. High prevalence of celiac disease among patients with insulin-dependent (type I) diabetes mellitus. Am J Gastroenterol 1997; 92 (12):2210-2212.
(224) Not T, Tommasini A, Tonini G, Buratti E, Pocecco M, Tortul C et al. Undiagnosed coeliac disease and risk of autoimmune disorders in subjects with Type I diabetes mellitus. diabetol 2001; 44 (2):151-155.
(225) Oelkers W, Diederich S, Bahr V. Therapeutic strategies in adrenal insufficiency. Ann Endocrinol (Paris) 2001; 62 (2):212-216.
(226) De Bellis AA, Falorni A, Laureti S, Perrino S, Coronella C, Forini F et al. Time course of 21-hydroxylase antibodies and long-term remission of subclinical autoimmune adrenalitis after corticosteroid therapy: case report. J Clin Endocrinol Metab 2001; 86 (2):675-678.
(227) Hu CY, Rodriguez-Pinto D, Du W, Ahuja A, Henegariu O, Wong FS et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 2007; 117 (12):3857-3867.
(228) El Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Hegedus L. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. J Clin Endocrinol Metab 2007; 92 (5):1769-1772.
(229) Salvi M, Vannucchi G, Campi I, Curro N, Dazzi D, Simonetta S et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 2007; 156 (1):33-40.
(230) El Fassi D, Nielsen CH, Kjeldsen J, Clemmensen O, Hegedus L. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut 2008; 57 (5):714-715.
(231) Bresson D, Togher L, Rodrigo E, Chen YL, Bluestone JA, Herold KC et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. Journal of Clinical Investigation 2006; 116 (5):1371-1381.
(232) Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC. TCR stimulation with modified anti-CD3 mAb expands CD8 T cell population and induces CD8CD25 Tregs. J Clin Invest 2005; 115 (10):2904-2913.
(233) Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D et al. A Single Course of Anti-CD3 Monoclonal Antibody hOKT3{gamma}1 (Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes. diab 2005; 54 (6):1763-1769.
(234) Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346 (22):1692-1698.
(235) Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352 (25):2598-2608.
(236) Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007; 7 (8):622-632.
(237) Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 2008; 9 (3):239-244.
(238) Masteller EL, Warner MR, Tang Q, Tarbell KV, McDevitt H, Bluestone JA. Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J Immunol 2005; 175 (5):3053-3059.
(239) Bacchetta R, Passerini L, Gambineri E, Dai M, Allan SE, Perroni L et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest 2006; 116 (6):1713-1722.
(240) Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4 (4):330-336.
(241) Mazzolari E, Forino C, Fontana M, D'Ippolito C, Lanfranchi A, Gambineri E et al. A new case of IPEX receiving bone marrow transplantation. Bone Marrow Transplant 2005; .
(242) Zhan H, Sinclair J, Adams S, Cale CM, Murch S, Perroni L et al. Immune reconstitution and recovery of FOXP3 (forkhead box P3)-expressing T cells after transplantation for IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) syndrome. Pediatrics 2008; 121 (4):e998-1002.
(243) Rao A, Kamani N, Filipovich A, Lee SM, Davies SM, Dalal J et al. Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. Blood 2007; 109 (1):383-385.
(244) Bindl L, Torgerson T, Perroni L, Youssef N, Ochs HD, Goulet O et al. Successful use of the new immune-suppressor sirolimus in IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome). J Pediatr 2005; 147 (2):256-259.
(245) Rosenstein ED, Advani S, Reitz RE, Kramer N. The prevalence of insulin receptor antibodies in patients with systemic lupus erythematosus and related conditions. J Clin Rheumatol 2001; 7 (6):371-373.
(246) Kato Y, Ichiki Y, Kitajima Y. A case of systemic lupus erythematosus presenting as hypoglycemia due to anti-insulin receptor antibodies. Rheumatol Int 2008; .
(247) Page KA, Dejardin S, Kahn CR, Kulkarni RN, Herold KC, Inzucchi SE. A patient with type B insulin resistance syndrome, responsive to immune therapy. Nat Clin Pract Endocrinol Metab 2007; 3 (12):835-840.
(248) Palmieri G, Lastoria S, Colao A, Vergara E, Varrella P, Biondi E et al. Successful treatment of a patient with a thymoma and pure red-cell aplasia with octreotide and prednisone. N Engl J Med 1997; 336 (4):263-265.
(249) Marx A, Wilisch A, Schultz A, Gattenlohner S, Nenninger R, Muller-Hermelink HK. Pathogenesis of myasthenia gravis. Virchows Arch 1997; 430:355-364.
(250) Mygland A, Aarli JA, Matre R, Gilhus NE. Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis. J Neurol Neurosurg Psychiatr 1995; 57:843-846.
(251) Inada K, Okumura M, Shiono H, Inoue M, Kadota Y, Ohta M et al. Role of positive selection of thymoma-associated T cells in the pathogenesis of myasthenia gravis. J Surg Res 2005; 126 (1):34-40.
(252) Kondo K, Monden Y. Thymoma and myasthenia gravis: a clinical study of 1,089 patients from Japan. Ann Thorac Surg 2005; 79 (1):219-224.
(253) Suzuki S, Shimoda M, Kawamura M, Sato H, Nogawa S, Tanaka K et al. Myasthenia gravis accompanied by alopecia areata: clinical and immunogenetic aspects. Eur J Neurol 2005; 12 (7):566-570.
(254) Geuder KI, Marx A, Witzemann V, Schalke B, Kirchner T, Müller-Hermelink HK. Genomic organization and lack of transcription of the nicotinic acetylcholine receptor subunit genes in myasthenia gravis-associated thymoma. Lab Invest 1992; 452:458.
(255) Offerhaus GJ, Schipper ME, Lazenby AJ, Montgomery E, Morsink FH, Bende RJ et al. Graft-versus-host-like disease complicating thymoma: lack of AIRE expression as a cause of non-hereditary autoimmunity? Immunol Lett 2007; 114 (1):31-37.
(256) Strobel P, Murumagi A, Klein R, Luster M, Lahti M, Krohn K et al. Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). J Pathol 2007; 211 (5):563-571.
(257) Amiel LL, Machover D, Droz JP. Dyscrasie plasmocytaire avec arteriopathie, polyneuropathie, syndrome endocrinien. Ann Intern Med 1975; 745:749.
(258) Kim DE, Kim HJ, Kim YA, Lee KW. Kaposi's sarcoma herpesvirus-associated Castleman's disease with POEMS syndrome. Muscle Nerve 2000; 23 (3):436-439.
(259) Dispenzieri A, Moreno-Aspitia A, Suarez GA, Lacy MQ, Colon-Otero G, Tefferi A et al. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood 2004; 104 (10):3400-3407.
(260) Watanabe O, Maruyama I, Arimura K, Kitajima I, Arimura H, Hanatani M et al. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve 1998; 21 (11):1390-1397.
(261) Soubrier M, Dubost JJ, Serre AF, Ristori JM, Sauvezie B, Cathebras P et al. Growth factors in POEMS syndrome: evidence for a marked increase in circulating vascular endothelial growth factor. Arthritis Rheum 1997; 40:786-787.
(262) Dietrich PY, Duchosal MA. Bevacizumab therapy before autologous stem-cell transplantation for POEMS syndrome. Ann Oncol 2008; 19 (3):595.
(263) Kuwabara S, Misawa S, Kanai K, Sawai S, Hattori T, Nishimura M et al. Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome. J Neurol Neurosurg Psychiatry 2008; .
(264) Cavaco B, Uchigata Y, Porto T, Amparo-Santos M, Sobrinho L, Leite V. Hypoglycaemia due to insulin autoimmune syndrome: report of two cases with characterisation of HLA alleles and insulin autoantibodies. Eur J Endocrinol 2001; 145 (3):311-316.
(265) Scully RE, Mark EJ, McNeely WF, McNeely BU. Case records of the Massachusetts General Hospital: Case 34-1987. N Engl J Med 1987; 317:493-501.
(266) Rabinowe SL, Rubin IL, George KL, Adri MN, Eisenbarth GS. Trisomy 21 (Down's syndrome): autoimmunity, aging and monoclonal-antibody defined T-cell abnormalities. J Autoimmun 1989; 2:25-30.
(267) Inoue H, Tanizawa Y, Wasson J, Behn P, Kalidas K, Bernal-Mizrachi E et al. A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome). Nat Genet 1998; 20:143-148.
(268) Barrett TG, Bundey SE, Macleod AF. Neurodegenration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet 1995; 346:1458-1463.
(269) Karasik A, O'Hara C, Srikanta S, Swift M, et al. Genetically programmed selective islet beta-cell loss in diabetic subjects with Wolfram's syndrome. Diab care 1989; 12:135-138.
(270) Ou D, Jonsen LA, Metzger DL, Tingle AJ. CD4+ and CD8+ T-cell clones from congenital rubella syndrome patients with IDDM recognize overlapping GAD65 protein epitopes. Implications for HLA class I and II allelic linkage to disease susceptibility. Hum Immunol 1999; 60 (8):652-664.
(271) Rabinowe SL, George KL, Loughlin R, Soeldner JS, Eisenbarth GS. Congenital rubella. Monoclonal antibody-defined T cell abnormalities in young adults. Am J Med 1986; 81 (5):779-782.
(272) Berio A, Piazzi A. A case of Kearns-Sayre syndrome with autoimmune thyroiditis and possible Hashimoto encephalopathy. Panminerva Med 2002; 44 (3):265-269.
(273) Katsanos KH, Elisaf M, Bairaktari E, Tsianos EV. Severe hypomagnesemia and hypoparathyroidism in Kearns-Sayre syndrome. Am J Nephrol 2001; 21 (2):150-153.
(274) Artuch R, Pavia C, Playan A, Vilaseca MA, Colomer J, Valls C et al. Multiple endocrine involvement in two pediatric patients with Kearns-Sayre syndrome. Horm Res 1998; 50 (2):99-104.
(275) Yamashita S, Nishino I, Nonaka I, Goto Y. Genotype and phenotype analyses in 136 patients with single large-scale mitochondrial DNA deletions. J Hum Genet 2008; 53 (7):598-606.
(276) Remes AM, Majamaa-Voltti K, Karppa M, Moilanen JS, Uimonen S, Helander H et al. Prevalence of large-scale mitochondrial DNA deletions in an adult Finnish population. Semin Neurol 2005; 64 (6):976-981.
(277) Pennings RJ, Dikkeschei LD, Cremers CW, van den Ouweland JM. [From gene to disease; mutations in the WFS1-gene as the cause of juvenile type I diabetes mellitus with optic atrophy (Wolfram syndrome)]. Ned Tijdschr Geneeskd 2002; 146 (21):985-987.
(278) Yamaguchi S, Ishihara H, Tamura A, Yamada T, Takahashi R, Takei D et al. Endoplasmic reticulum stress and N-glycosylation modulate expression of WFS1 protein. Biochem Biophys Res Commun 2004; 325 (1):250-256.
(279) Viskari H, Paronen J, Keskinen P, Simell S, Zawilinska B, Zgorniak-Nowosielska I et al. Humoral beta-cell autoimmunity is rare in patients with the congenital rubella syndrome. Clin Exp Immunol 2003; 133 (3):378-383.
(280) Karounos DG, Wolinsky JS, Thomas JW. Monoclonal antibody to rubella virus capsid protein recognizes a b-cell antigen. J Immunol 1993; 150:3080-3085.
(281) Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974; 2 (7892):1279-1283.
(282) Weetman AP. Determinants of autoimmune thyroid disease. Nat Immunol 2001; 2 (9):769-770.
(283) Benoist C, Mathis D. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nat Immunol 2001; 2 (9):797-801.